Search Result

Results for "

pi3k_gamma_- Inhibitor -1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) Apoptosis (16) ATM/ATR (1) Autophagy (8) CDK (1) DNA-PK (3) Epigenetic Reader Domain (1) HDAC (1) Isotope-Labeled Compounds (2) Mitophagy (5) mTOR (18) PARP (1) PI3K (62) Reactive Oxygen Species (4)
By Research Areas:	Cancer (56) Inflammation/Immunology (10) Metabolic Disease (1) Neurological Disease (1)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-111570

AZ2	PI3K	Inflammation/Immunology
AZ2 is a highly selective *PI3Kγ* inhibitor (The pIC₅₀ value for *PI3Kγ* is 9.3). AZ2 can be used for the research of inflammatory and immune diseases ^[1].

HY-148317

PI3Kγ inhibitor 6	PI3K	Inflammation/Immunology
PI3Kγ inhibitor 6 (compound 9) is a *PI3Kγ* inhibitor. PI3Kγ inhibitor 6 can be used for the research of inflammatory and autoimmune diseases ^[1].

HY-132299

PI3Kγ inhibitor 4	PI3K	Inflammation/Immunology
PI3Kγ inhibitor 4 is a potent, selective and orally active inhibitor of *PI3Kγ, with an IC₅₀* of 40 nM. PI3Kγ inhibitor 4 shows ∼7, 43, and 18-fold selectivity for PI3Kγ over the α, β, and δ isoforms, respectively. PI3Kγ inhibitor 4 can be used for the research of airway inflammation ^[1].

HY-112286

PI3Kγ inhibitor 2

PI3K Inflammation/Immunology

PI3Kγ inhibitor 2 (Compound 16) is an orally bioavailable, CNS-penetrant, isoform selective PI3Kγ inhibitor with a K_i of 4 nM ^[1].

PI3Kγ inhibitor 2	PI3K	Inflammation/Immunology
PI3Kγ inhibitor 2 (Compound 16) is an orally bioavailable, CNS-penetrant, isoform selective *PI3Kγ* inhibitor with a K_i of 4 nM ^[1].

HY-153703

PI3Kγ inhibitor 7	PI3K	Cancer
PI3Kγ inhibitor 7 (compound 2) is a potent and orally active *PI3Kγ* inhibitor with IC₅₀ values of 4768, 878.1, 3.42, 355.2 nM for PI3Kα, PI3Kβ, PI3Kγ, PI3Kδ, respectively. PI3Kγ inhibitor 7 shows antitumor activity ^[1]. PI3Kγ inhibitor 7 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-10549

PI3Kγ inhibitor 1

PI3K Cancer

PI3Kγ inhibitor 1 is a PI3Kδ and PI3Kγ inhibitor extracted from patent WO2014004470A1, Compound 168 in Table 4, has IC₅₀s of <100 nM.

PI3Kγ inhibitor 1	PI3K	Cancer
PI3Kγ inhibitor 1 is a PI3Kδ and *PI3Kγ* inhibitor extracted from patent WO2014004470A1, Compound 168 in Table 4, has IC₅₀s of <100 nM.

HY-112443

AZD3458	PI3K	Metabolic Disease Inflammation/Immunology Cancer
AZD3458 is a potent and remarkably selective *PI3Kγ* inhibitor with pIC₅₀s of 9.1, 5.1, <4.5, and 6.5 for *PI3Kγ, PI3Kα, PI3Kβ, and PI3K*δ, respectively ^[1].

HY-16122A

CAL-130

PI3K Cancer

CAL-130 is a PI3Kδ and PI3Kγ inhibitor with IC₅₀s of 1.3 and 6.1 nM, respectively.
HY-16122B

CAL-130 Hydrochloride

PI3K Cancer

CAL-130 is a PI3Kδ and PI3Kγ inhibitor with IC₅₀s of 1.3 and 6.1 nM, respectively.

CAL-130	PI3K	Cancer
CAL-130 is a PI3Kδ and *PI3Kγ* inhibitor with IC₅₀s of 1.3 and 6.1 nM, respectively.

CAL-130 Hydrochloride	PI3K	Cancer
CAL-130 is a PI3Kδ and *PI3Kγ* inhibitor with IC₅₀s of 1.3 and 6.1 nM, respectively.

HY-13531

AS-604850 1 Publications Verification	PI3K	Cancer
AS-604850 is a potent, selective and ATP-competitive *PI3Kγ* inhibitor with an IC₅₀ value of 0.25 μM and a K_i value of 0.18 μM. AS-604850 shows isoform selective inhibitor of *PI3Kγ* with over 30-fold selectivity for PI3Kδ and β, and 18-fold selectivity over PI3Kα, respectively ^[1].

HY-161366

OMS14	PI3K	Cancer
OMS14 is exhibits inhibitory activity for phosphoinositide 3-kinase γ (PI3Kγ) and *PIK3CD/PIK3R1, which inhibits* 19% PI3Kγ and 65% PIK3CD/PIK3R1 activity at 100 μM. OMS14 exhibits anticancer efficacy in various cancer cells ^[1].

HY-100716

Eganelisib 10+ Cited Publications Ipi-549	PI3K	Cancer
Eganelisib (IPI549) is a potent and selective *PI3Kγ* inhibitor with an IC₅₀ of 16 nM. Eganelisib shows >100-fold selectivity over other lipid and protein kinases ^[1].

HY-112172

Tenalisib R Enantiomer RP6530 R Enantiomer	PI3K	Cancer
Tenalisib R Enantiomer (RP6530 R Enantiomer) is an R enantiomer of Tenalisib. Tenalisib is a potent and selective PI3Kδ and PI3Kγ inhibitor with IC₅₀ values of 25 and 33 nM, respectively ^[1] .

HY-133907

NVS-PI3-4

PI3K Inflammation/Immunology Cancer

NVS-PI3-4 is a specific PI3Kγ inhibitor. NVS-PI3-4 can be used for the research of allergies, inflammatory and cancer diseases ^[1] .

NVS-PI3-4	PI3K	Inflammation/Immunology Cancer
NVS-PI3-4 is a specific *PI3Kγ* inhibitor. NVS-PI3-4 can be used for the research of allergies, inflammatory and cancer diseases ^[1] .

HY-120438

TASP0415914	PI3K Akt	Inflammation/Immunology
TASP0415914 is a potent and orally active *PI3Kγ* inhibitor with an IC₅₀ of 29 nM. TASP0415914 also shows potent Akt inhibitory activities with an IC₅₀ of 294 nM. TASP0415914 can be used for inflammatory diseases research ^[1].

HY-D0254

Gallein 4 Publications Verification Pyrogallol phthalein	PI3K	Cancer
Gallein is a G protein βγ (Gβγ) subunit signalling inhibitor. Gallein disrupts the interaction of Gβγ subunits with the PI3Kγ. Anticancer agent ^[1]. Gallein used as a red dye, an acid-base indicator and as a detection reagent for phosphates .

HY-15271

WYE-687 3 Publications Verification	mTOR PI3K	Cancer
WYE-687 is an ATP-competitive mTOR inhibitor with an IC₅₀ of 7 nM. WYE-687 concurrently inhibits activation of *mTORC1* and mTORC2. WYE-687 also inhibits PI3Kα and *PI3Kγ* with IC₅₀s of 81 nM and 3.11 μM, respectively.

HY-10681

Gedatolisib 4 Publications Verification PKI-587; PF-05212384	PI3K mTOR	Cancer
Gedatolisib (PKI-587) is a highly potent dual inhibitor of PI3Kα, *PI3Kγ, and mTOR* with IC₅₀s of 0.4 nM, 5.4 nM and 1.6 nM, respectively ^[1]. Gedatolisib is equally effective in both complexes of mTOR, *mTORC1* and mTORC2 .

HY-15271A

WYE-687 dihydrochloride	mTOR PI3K	Cancer
WYE-687 dihydrochloride is an ATP-competitive mTOR inhibitor with an IC₅₀ of 7 nM ^[1]. WYE-687 dihydrochloride concurrently inhibits activation of *mTORC1* and mTORC2 . WYE-687 also inhibits PI3Kα and *PI3Kγ* with IC₅₀s of 81 nM and 3.11 μM, respectively ^[1].

HY-18085

Quercetin Maximum Cited Publications 57 Publications Verification	PI3K Autophagy Mitophagy Reactive Oxygen Species Apoptosis	Cancer
Quercetin, a natural flavonoid, is a stimulator of recombinant *SIRT1* and also a *PI3K* inhibitor with IC₅₀ of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively ^[1].

HY-18085A

Quercetin hydrate	PI3K Autophagy Mitophagy Apoptosis Reactive Oxygen Species	Cancer
Quercetin hydrate, a natural flavonoid, is a stimulator of recombinant *SIRT1* and also a *PI3K* inhibitor with IC₅₀ of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively ^[1].

HY-19962

Paxalisib 2 Publications Verification GDC-0084
Paxalisib (GDC-0084) is a brain penetrant inhibitor of *PI3K* and mTOR, with K_is of 2 nM, 46 nM, 3 nM, 10 nM and 70 nM for PI3Kα PI3Kβ, PI3Kδ, PI3Kγ and mTOR, respectively ^[1].

HY-N0146

Quercetin dihydrate Maximum Cited Publications 57 Publications Verification	PI3K Apoptosis	Inflammation/Immunology Cancer
Quercetin dihydrate, a natural flavonoid, is a stimulator of recombinant *SIRT1* and a *PI3K* inhibitor with *IC₅₀s of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K* δ and PI3K β, respectively ^[1].**

HY-13898

Taselisib 15+ Cited Publications GDC-0032; RG-7604	PI3K	Cancer
Taselisib (GDC-0032) is a potent *PI3K* inhibitor targets PIK3CA mutations, with K_is of 0.12 nM, 0.29 nM, 0.97 nM, and 9.1 nM for PI3Kδ, PI3Kα, PI3Kγ and PI3Kβ, respectively.

HY-147419

Vulolisib	PI3K	Cancer
Vulolisib is a potent and orally active phosphatidylinositol 3-kinase (PI3K) inhibitor, with IC₅₀ values of 0.2 nM, 168 nM, 90 nM and 49 nM for PI3Kα, PI3Kβ, PI3Kγ and PI3Kδ, respectively. Antiproliferative and antineoplastic activity ^[1].

HY-12034

WYE-354 5 Publications Verification	mTOR Autophagy Apoptosis	Cancer
WYE-354 is an ATP-competitive mTOR inhibitor with an IC₅₀ of 5 nM. WYE-354 also inhibits PI3Kα and *PI3Kγ* with IC₅₀s of 1.89 μM and 7.37 μM, respectively. WYE-354 inhibits both *mTORC1* and mTORC2. WYE-354 induces autophagy activation in vitro .

HY-13431

KU-0060648 1 Publications Verification	DNA-PK PI3K mTOR	Cancer
KU-0060648 is a dual inhibitor of *PI3K* and DNA-PK with IC₅₀s of 4 nM, 0.5 nM, 0.1 nM, 0.594 nM and 8.6 nM for PI3Kα, PI3Kβ, PI3Kγ, PI3Kδ and DNA-PK, respectively ^[1].

HY-18085S1

Quercetin-d3	Isotope-Labeled Compounds PI3K Autophagy Mitophagy Reactive Oxygen Species Apoptosis	Cancer
Quercetin-d₃ is the deuterium labeled Quercetin. Quercetin, a natural flavonoid, is a stimulator of recombinant SIRT1 and also a PI3K inhibitor with IC50 of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively[1].

HY-18085S

Quercetin-d5	PI3K Autophagy Mitophagy Apoptosis	Cancer
Quercetin-d₅ is a deuterium labeled Quercetin. Quercetin, a natural flavonoid, is a stimulator of recombinant SIRT1 and also a PI3K inhibitor with IC50 of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively[1].

HY-101517

PI3K-IN-2	PI3K	Cancer
PI3K-IN-2 (compound 10) is a potent and orally active PI3Kβ/δ (IC₅₀=7.1/8.6 nM) inhibitor with excellent selectivity versus PI3Kσ and PI3Kγ (IC₅₀=13/190 nM, respectively) ^[1].

HY-13334

BGT226 maleate 5 Publications Verification NVP-BGT226 maleate	PI3K mTOR Autophagy Apoptosis	Cancer
BGT226 (NVP-BGT226 maleate) is a *PI3K* (with IC₅₀s of 4 nM, 63 nM and 38 nM for PI3Kα, PI3Kβ and *PI3Kγ) /mTOR* dual inhibitor which displays potent growth-inhibitory activity against human head and neck cancer cells ^[1] .

HY-18085S2

Quercetin-13C3	Isotope-Labeled Compounds PI3K Autophagy Mitophagy Reactive Oxygen Species Apoptosis	Cancer
Quercetin- ¹³C₃ is the ¹³C-labeled Quercetin. Quercetin, a natural flavonoid, is a stimulator of recombinant SIRT1 and also a PI3K inhibitor with IC50 of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively[1].

HY-143404

PI3K-IN-30

PI3K Cancer

PI3K-IN-30 (compound 6d) is a potent PI3K inhibitor with IC₅₀s of 5.1, 136, 30.7 and 8.9 nM for PI3Kα, PI3Kβ, PI3Kγ and PI3Kδ, respectively ^[1].

PI3K-IN-30	PI3K	Cancer
PI3K-IN-30 (compound 6d) is a potent *PI3K* inhibitor with IC₅₀s of 5.1, 136, 30.7 and 8.9 nM for PI3Kα, PI3Kβ, PI3Kγ and PI3Kδ, respectively ^[1].

HY-155996

FD2157	PI3K Apoptosis	Cancer
FD2157 is a photosensitive *PI3K* inhibitor, with IC₅₀s of 43 nM, 83 nM, 84 nM, 14 nM for PI3Kα, PI3Kβ, PI3Kγ, PI3Kδ respectively. FD2157 potently inhibits cancer cell proliferation and induces cell apoptosis when exposed to 365 nm UV light ^[1].

HY-147285

PI3K/mTOR Inhibitor-9	mTOR PI3K	Neurological Disease
PI3K/mTOR Inhibitor-9 (Compound 1) is a potent mTOR and *PI3K* inhibitor with IC₅₀ values of 38 nM, 6.6 μM, 6.6 μM and 0.8 μM against mTOR (phospho-S6 cellular assay), PI3Kα, PI3Kγ and PI3Kδ, respectively ^[1].

HY-150638

PI3Kδ/γ-IN-3	PI3K Apoptosis	Cancer
PI3Kδ/γ-IN-3 (Compound 58) is a potent and orally active PI3Kδ and *PI3Kγ* dual inhibitor with IC₅₀s of 1 nM and 16 nM, respectively. PI3Kδ/γ-IN-3 induces tumor cell apoptosis and can be used for B-cell malignancies research ^[1].

HY-139810

ETP-47037	PI3K	Others
ETP-47037 is a potent and inhibitor of PI3Kα isoform with an IC₅₀ value of 0.99 nM. ETP-47037 also inhibits the PI3Kβ, PI3Kδ, and PI3Kγ isoforms, with IC₅₀ values of 49.2, 7.13, and 49.1 nM, respectively. ETP-47037 has the potential for the research of chemical modulation of telomere protection ^[1].

HY-16585

VS-5584 5 Publications Verification SB2343	PI3K mTOR	Cancer
VS-5584 is a *pan-PI3K/mTOR* kinase inhibitor with IC₅₀s of 16 nM, 68 nM, 42 nM, 25 nM, and 37 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ and mTOR, respectively. VS-5584 simultaneously blocks mTORC2 as well as *mTORC1*.

HY-12868

Bimiralisib 3 Publications Verification PQR309	PI3K mTOR	Cancer
Bimiralisib (PQR309) is a potent, brain-penetrant, orally bioavailable, pan-class I *PI3K/mTOR* inhibitor with IC₅₀s of 33 nM, 451 nM, 661 nM, 708 nM and 89 nM for PI3Kα, PI3Kδ, PI3Kβ, *PI3Kγ* and mTOR, respectively. Bimiralisib is an *mTORC1* and mTORC2 inhibitor.

HY-118521

AS-041164	PI3K	Inflammation/Immunology
AS-041164 is a potent, selective and orally active *PI3Kγ* isoform inhibitor with an IC₅₀ of 70 nM. AS-041164 shows less activity against PI3Kα, PI3Kβ, and PI3Kδ (IC₅₀s of 240 nM, 1.45 μM, and 1.70 μM, respectively). AS-041164 has anti-inflammatory effects ^[1].

HY-146789

PI3Kδ/γ-IN-2	PI3K	Cancer
PI3Kδ/γ-IN-2 is a potent PI3Kδ and *PI3Kγ* dual inhibitor with IC₅₀s of 1 nM and 4.3 nM, respectively. PI3Kδ/γ-IN-2 has favorable oral bioavailability. PI3Kδ/γ-IN-2 has potential for battling B-cell malignancies ^[1].

HY-123849

SN32976	PI3K mTOR	Cancer
SN32976 is a potent and selective class I *PI3K* and mTOR inhibitor with IC₅₀s of 15.1 nM, 461 nM, 110 nM, 134 nM and 194 nM for PI3Kα, PI3Kβ, *PI3Kγ, PI3Kδ and mTOR*, respectively. SN32976 shows high selectivity among other 442 kinases. SN32976 shows anticancer effects ^[1].

HY-111508

PI3K/mTOR Inhibitor-2 1 Publications Verification	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-2 is a potent dual pan-PI3K/mTOR inhibitor with IC₅₀s of 3.4/34/16/1 nM for PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ and 4.7 nM for mTOR ^[1]. Antitumor activity ^[1].

HY-108418

PI3Kδ-IN-15	PI3K	Cancer
PI3Kδ-IN-15 (compound 6b) is a selective PI3Kδ inhibitor with an IC₅₀ of 0.5 nM for p110δ. PI3Kδ-IN-15 inhibits PI3Kδ with >30-fold higher potency than PI3Kγ, PI3Kβ, and PI3Kα ^[1].

HY-112614

ATM Inhibitor-1	ATM/ATR	Cancer
ATM Inhibitor-1 is a highly potent, selective and orally active ATM inhibitor, with an IC₅₀ of 0.7 nM, shows weak activity against mTOR (IC₅₀, 21 μM), DNAPK (IC₅₀, 2.8 μM), PI3Kα (IC₅₀, 3.8 μM), PI3Kβ (IC₅₀, 10.3 μM), PI3Kγ (IC₅₀, 3 μM) and PI3Kδ (IC₅₀, 0.73 μM). ATM Inhibitor-1 exhibits anti-tumor activity ^[1].

HY-143403

PI3K-IN-31	PI3K	Cancer
PI3K-IN-31 (Compound 6b) is a potent *PI3K* inhibitor with IC₅₀s of 3.7 nM, 74 nM, 14.6 nM, and 9.9 nM for PI3Kα, PI3Kβ, *PI3Kγ, and PI3K*δ, respectively. PI3K-IN-31 has anticancer effects ^[1].

HY-144806

PI3K/AKT-IN-1 5+ Cited Publications	PI3K Akt Apoptosis	Cancer
PI3K/AKT-IN-1 is an effective *PI3K/AKT* dual inhibitor (IC₅₀ of 6.99, 4.01 and 3.36 μM for PI3Kγ, PI3Kδ and AKT, respectively). PI3K/AKT-IN-1 has anticancer activity and acts by inhibiting PI3K/AKT axis and inducing caspase 3 dependent apoptosis ^[1].

HY-12513

Samotolisib 4 Publications Verification LY3023414	PI3K DNA-PK mTOR Autophagy	Cancer
Samotolisib (LY3023414) potently and selectively inhibits class I PI3K isoforms, DNA-PK, and *mTORC1/2* with IC₅₀s of 6.07 nM, 77.6 nM, 38 nM, 23.8 nM, 4.24 nM and 165 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ, DNA-PK and mTOR, respectively. Samotolisib potently inhibits *mTORC1*/2 at low nanomolar concentrations ^[1] .

HY-110109

ETP-45658	PI3K DNA-PK mTOR	Cancer
ETP-45658 is a potent *PI3K* inhibitor, with IC₅₀s of 22.0 nM, 39.8 nM, 129.0 nM and 717.3 nM for PI3Kα, PI3Kδ, PI3Kβ and *PI3Kγ, respectively. ETP-45658 also can inhibit* DNA-PK (IC₅₀=70.6 nM) and mTOR (IC₅₀=152.0 nM). ETP-45658 can be used for the research of cancer ^[1] .

HY-153894

SRX3177	CDK Epigenetic Reader Domain PI3K	Cancer
SRX3177 is a triple inhibitor of CDK4/6, *PI3K, and BRD4, with IC₅₀s of 33 nM (BRD4 BD1), 89 nM (BRD4 BD2), 79 nM (PI3Kα), 83 nM (PI3Kδ), 3.18 μM (PI3Kγ*), <2.5 nM (CDK4), 3.3 nM (CDK6), respectively. SRX3177 exerts broad cytotoxic activity against cancer cells, but acts friendly with normal epithelial cells ^[1].

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-18085

Quercetin Maximum Cited Publications 57 Publications Verification	Flavonols Structural Classification Classification of Application Fields Anti-aging Source classification Endocrine diseases Plants Endogenous metabolite Human Gut Microbiota Metabolites Flavonoids other families Microorganisms Immune System Disorder Sunscreen Leguminosae Disease markers Cosmetic Research Disease Research Fields Glycyrrhiza uralensis Fisch. Cancer	PI3K Autophagy Mitophagy Reactive Oxygen Species Apoptosis
Quercetin, a natural flavonoid, is a stimulator of recombinant *SIRT1* and also a *PI3K* inhibitor with IC₅₀ of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively ^[1].

HY-N0146

Quercetin dihydrate Maximum Cited Publications 57 Publications Verification	Flavonols Structural Classification Flavonoids other families Classification of Application Fields Source classification Phenols Polyphenols Plants Disease Research Fields Cancer	PI3K Apoptosis
Quercetin dihydrate, a natural flavonoid, is a stimulator of recombinant *SIRT1* and a *PI3K* inhibitor with *IC₅₀s of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K* δ and PI3K β, respectively ^[1].**

HY-18085A

Quercetin hydrate	Structural Classification Flavonols Flavonoids other families Source classification Plants	PI3K Autophagy Mitophagy Apoptosis Reactive Oxygen Species
Quercetin hydrate, a natural flavonoid, is a stimulator of recombinant *SIRT1* and also a *PI3K* inhibitor with IC₅₀ of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively ^[1].

Cat. No.	Product Name	Chemical Structure

HY-18085S1

Quercetin-d3
Quercetin-d₃ is the deuterium labeled Quercetin. Quercetin, a natural flavonoid, is a stimulator of recombinant SIRT1 and also a PI3K inhibitor with IC50 of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively[1].

HY-18085S

Quercetin-d5
Quercetin-d₅ is a deuterium labeled Quercetin. Quercetin, a natural flavonoid, is a stimulator of recombinant SIRT1 and also a PI3K inhibitor with IC50 of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively[1].

HY-18085S2

Quercetin-13C3
Quercetin- ¹³C₃ is the ¹³C-labeled Quercetin. Quercetin, a natural flavonoid, is a stimulator of recombinant SIRT1 and also a PI3K inhibitor with IC50 of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively[1].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

pi3k_gamma_- Inhibitor -1

Inhibitors & Agonists

NaturalProducts

Isotope-Labeled Compounds

Natural
Products